Diagnostic accuracy of fecal calprotectin in predicting endoscopic severity among IBD patients
نویسندگان
doi
10.48309/jmpcr.2026.567628.1952چکیده
The purpose of this investigation was to determine the relationship between fecal calprotectin and the severity scores of the colonoscopy score of patients with inflammatory bowel disease (IBD). 40 patients with IBD (21 patients with ulcerative colitis and 19 patients with Crohn's disease) and 40 healthy controls were enrolled. The ELISA technique was used to measure the fecal calprotectin level. Endoscopic severity was determined by using the Mayo score for ulcerative colitis and the SES-CD score of Crohn's disease. Statistical tests involved the Spearman correlation test to evaluate the relationship between fecal calprotectin and endoscopic scores, ANOVA to evaluate calprotectin levels in different groups of severity, and ROC curve analysis to calculate diagnostic cut-off values. It was discovered that there is a significant positive correlation between endoscopic severity scores and fecal calprotectin levels in both Crohn disease (r = 0.68, P < 0.001) and ulcerative colitis (r = 0.75, P < 0.001). The level of fecal calprotectin was greatly increased in patients with moderate to severe disease compared to patients with mild disease. The best diagnostic cut-off points for predicting moderate to severe disease activity were 200 µg/g with a sensitivity of 85, a specificity of 78, and an AUC of 0.91. Fecal calprotectin is a stable non-invasive biomarker that is highly related to endoscopic severity scores in IBD patients. It could be used to measure the disease activity and forecast moderate to severe disease, as it provides an alternative to regular colonoscopies in clinical practice.